Retraction: 2-Tellurium-bridged β-cyclodextrin, a thioredoxin reductase inhibitor, sensitizes human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression (Carcinogenesis (2011) 32:2 (154-167) DOI: 10.1093/carcin/bgq234);2-Tellurium-bridged β-cyclodextrin, A thioredoxin reductase inhibitor, sensitizes human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression

Carcinogenesis

Volumn 32, Issue 2, 2011, Pages 154-167

  Lin, Tingting ^a,b   Ding, Zhiying ^b   Li, Nan ^a   Xu, Jiayun ^a   Luo, Guimin ^b   Liu, Junqiu ^a   Shen, Jiacong ^a  

^a Jilin University   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 TELLURIUM BRIDGED BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; CASPASE 3; CASPASE 8; DEATH RECEPTOR 5; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORGANOTELLURIUM DERIVATIVE; OXIDOREDUCTASE INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; THIOREDOXIN REDUCTASE INHIBITOR; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; RECEPTOR UPREGULATION; SENSITIZATION; TUMOR XENOGRAFT;

EID: 79251560339     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgac038     Document Type: Erratum

References (50)

1. Walczak, H. et al. (1999) Tumoricidal activity of tumor necrosis factorrelated apoptosis-inducing ligand in vivo. Nat. Med., 5, 157-163.
2. Pan, G. et al. (1997) The receptor for the cytotoxic ligand TRAIL. Science, 276, 111-113.
3. Walczak, H. et al. (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J., 16, 5386-5397.
4. Degli-Esposti, M.A. et al. (1997) Cloning and characterization of TRAILR3, a novel member of the emerging TRAIL receptor family. J. Exp. Med., 186, 1165-1170.
5. Degli-Esposti, M.A. et al. (1997) The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity, 7, 813-820.
6. Emery, J.G. et al. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem., 273, 14363-14367.
7. Kischkel, F.C. et al. (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J, 14, 5579-5588.
8. Kischkel, F.C. et al. (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity, 12, 611-620.
9. Boatright, K.M. et al. (2003) A unified model for apical caspase activation. Mol. Cell., 11, 529-541.
10. Schneider, P. et al. (1997) TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity, 7, 831-836.
11. Keane, M.M. et al. (2000) Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res. Treat., 64, 211-219.
12. Kreuz, S. et al. (2001) NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol., 21, 3964-3973.
13. Wang, C.Y. et al. (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 281, 1680-1683.
14. Rahman, M. et al. (2009) The TRAIL to targeted therapy of breast cancer. Adv. Cancer Res., 103, 43-73.
15. Zhang, Y. et al. (2008) TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol. Cancer Res., 6, 1861-1871.
16. Palacios, C. et al. (2006) Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res., 66, 8858-8869.
17. Fulda, S. et al. (2002) Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene, 21, 2283-2294.
18. Keane, M.M. et al. (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res., 59, 734-741.
19. Singh, T.R. et al. (2003) Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res., 63, 5390-5400.
20. Ren, X. et al. (2002) A novel cyclodextrin-derived tellurium compound with glutathione peroxidase activity. Chembiochem, 3, 356-363.
21. McNaughton, M. et al. (2004) Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth. J. Med. Chem., 47, 233-239.
22. Sun, Y. et al. (2005) The molecular mechanism of protecting cells against oxidative stress by 2-selenium-bridged beta-cyclodextrin with glutathione peroxidase activity. Biochim. Biophys. Acta., 1743, 199-204.
23. Luo, G.M. et al. (2003) Towards more efficient glutathione peroxidase mimics: substrate recognition and catalytic group assembly. Curr. Med. Chem., 10, 1151-1183.
24. Sies, H. (1993) Ebselen, a selenoorganic compound as glutathione peroxidase mimic. Free Radic. Biol. Med., 14, 313-323.
25. Dong, Z.Y. et al. (2006) Cyclodextrin-derived mimic of glutathione peroxidase exhibiting enzymatic specificity and high catalytic efficiency. Chemistry, 12, 3575-3579.
26. Dong, Z. et al. (2004) Aryl thiol substrate 3-carboxy-4-nitrobenzenethiol strongly stimulating thiol peroxidase activity of glutathione peroxidase mimic 2,2'-ditellurobis(2-deoxy-beta-cyclodextrin). J. Am. Chem. Soc., 126, 16395-16404.
27. Engman, L. et al. (2000) Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells. Anticancer Drug Des., 15, 323-330.
28. Urig, S. et al. (2006) On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol., 16, 452-465.
29. Nogueira, C.W. et al. (2004) Organoselenium and organotellurium compounds: toxicology and pharmacology. Chem. Rev., 104, 6255-6285.
30. Pennington, J.D. et al. (2007) Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr. Pharm. Des., 13, 3368-3377.
31. Wang, K. et al. (2009) Effect of 2-TeCD on the expression of adhesion molecules in human umbilical vein endothelial cells under the stimulation of tumor necrosis factor-alpha. Int. Immunopharmacol., 9, 1087-1091.
32. Yoshida, T. et al. (2001) Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett., 507, 381-385.
33. Aggarwal, B.B. (2000) Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol., 3, 745-756.
34. Ghosh, S. et al. (1990) Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature, 344, 678-682.
35. Kelley, S.K. et al. (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther., 299, 31-38.
36. Oya, M. et al. (2001) Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene, 20, 3888-3896.
37. Li, S. et al. (2000) The role of cellular glutathione peroxidase redox regulation in the suppression of tumor cell growth by manganese superoxide dismutase. Cancer Res., 60, 3927-3939.
38. Sharma, V. et al. (2008) Ebselen sensitizes glioblastoma cells to Tumor Necrosis Factor (TNFalpha)-induced apoptosis through two distinct pathways involving NF-kappaB downregulation and Fas-mediated formation of death inducing signaling complex. Int. J. Cancer., 123, 2204-2212.
39. Kretz-Remy, C. et al. (1996) Inhibition of IkB-a phosphorylation and degradation and subsequent NF-kB activation by glutathione peroxidase overexpression. J. Cell Biol., 133, 1083-1093.
40. Li, Q. et al. (2001) GPx-1 gene delivery modulates NFkappaB activation following diverse environmental injuries through a specific subunit of the IKK complex. Antioxid. Redox Signal., 3, 415-432.
41. Das, K.C. (2001) c-Jun NH2-terminal kinase-mediated redox-dependent degradation of IkappaB: role of thioredoxin in NF-kappaB activation. J. Biol. Chem., 276, 4662-4670.
42. Hayashi, T. et al. (1993) Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. J. Biol. Chem., 268, 11380-11388.
43. Wu, G.S. et al. (1997) KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet., 17, 141-143.
44. Su, R.Y. et al. (2008) 15-deoxy-Delta12,14-prostaglandin J2 up-regulates death receptor 5 gene expression in HCT116 cells: involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription. Mol. Cancer Ther., 7, 3429-3440.
45. Kim, Y.H. et al. (2004) Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis, 25, 1813-1820.
46. Baritaki, S. et al. (2008) Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL enhanced apoptosis in cancer cells. J. Immunol., 180, 6199-6210.
47. Higuchi, H. et al. (2004) Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J. Biol. Chem., 279, 51-60.
48. VanOosten,R.L. et al. (2005) Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol. Ther., 4, 1104-1112.
49. Sun, M. et al. (2008) Sp1 is involved in 8-chloro-adenosine-upregulated death receptor 5 expression in human hepatoma cells. Oncol. Rep., 19, 177-185.
50. Kim, J.Y. et al. (2008) Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation. J. Cell. Biochem., 105, 1386-1398.